Selinexor is an oral selective inhibitor of nuclear export ...

Karyopharm Therapeutics Inc. initiated a Phase 1/2 clinical trial for selinexor combined with standard therapy in glioblastoma (GBM) patients. Selinexor, an XPO1 inhibitor, shows promise in GBM treatment, with previous studies indicating its ability to cross the blood-brain barrier and exhibit anti-GBM activity. The trial aims to evaluate selinexor's efficacy in newly diagnosed and recurrent GBM patients, with primary endpoints focusing on progression-free and overall survival.